Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Riverwater Micro Opportunities Strategy Nathan Fredrick, CFA | “Delcath Systems (DCTH) is a commercial-stage oncology company focused on liver-directed cancer therapies. Its proprietary Hepzato Kit delivers high-dose chemotherapy directly to the liver while minimizing systemic exposure, allowing for targeted treatment of metastatic cancers that primarily affect the liver. The therapy is approved for ocular melanoma with liver metastases, with ongoing trials such as CHOPIN exploring first-line use. Despite recent volatility from slower site activations and Medicaid mix, management remains on track for rollout, with CHOPIN data expected in October as a key catalyst. BSD Analysis: Delcath is a high-risk med-tech story with a niche oncology platform that has shown promising clinical results but requires commercial execution the company hasn't yet proven. The TAM is meaningful, but adoption will depend heavily on reimbursement and physician education. Cash burn is aggressive, keeping dilution risk high. Still, the technology addresses a real unmet need. The stock trades like the company has no path forward — a typical microcap biotech overreaction. If early commercial traction appears, sentiment could flip quickly. A binary setup with potentially explosive upside.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
